Skip to content

Effectiveness of Telescopic Magnification in the Treatment of Amblyopia

Effectiveness of Telescopic Magnification in the Treatment of Amblyopia

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00970554
Enrollment
15
Registered
2009-09-02
Start date
2007-12-31
Completion date
2009-05-31
Last updated
2013-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia

Keywords

Amblyopia, Telescopic magnification, Patching

Brief summary

Amblyopia is a visual impairment of one eye that results from disuse of that eye during early brain development. The standard treatment for amblyopia consists of patching or pharmacological penalization of the sound eye. Unfortunately, approximately 50% of amblyopic children do not respond to these therapies, with poor compliance being a major factor in treatment failure. One new treatment strategy involves patching the sound eye while using a telescopic device on the amblyopic eye to magnify the images formed in the amblyopic eye. Children were randomized to receive either daily patching of the sound eye for 30 minutes only (patching only group), or daily patching of the sound eye for 30 minutes plus simultaneous use of a telescopic device by the amblyopic eye during patching (patching plus telescope group).

Detailed description

The goal of the present investigation was to conduct a prospective randomized clinical study to further evaluate the effectiveness of telescopic magnification plus patching vs patching alone on different types of amblyopia in patients who had failed previous treatment.

Interventions

OTHERPatching

Patching of the sound eye for 30 minutes a day for 17 weeks.

OTHERTelescopic magnification

Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.

Sponsors

The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Aged 4-17 years * Strabismic, refractive (anisometropic), isometropic or mixed mechanism amblyopia * Strabismic amblyopia is defined as amblyopia (1) in the presence of either an inability to maintain parallel visual axes (heterotropia) at distance or near fixation or both, or a history of strabismus surgery (or botulinum injection), and (2) in the absence of refractive error meeting the criteria below for mixed mechanism amblyopia * Refractive/Anisometropic amblyopia is defined as amblyopia in the presence of a difference in refractive error between the two eyes (anisometropia) of ≥0.5 diopter (D) of spherical equivalent or ≥1.5D of difference in astigmatism in any meridian, with no measurable heterophoria at distance or near fixation, which persisted after 12 weeks of spectacle correction * Isometropic amblyopia is defined as amblyopia in the presence a refractive error ≥5.0D of spherical equivalent in both eyes, but not meeting the criteria of anisometropic amblyopia * Mixed mechanism strabismic and refractive amblyopia is defined as the presence of both strabismic and anisometropic types of amblyopia * Ability to read the ETDRS letter chart * Visual acuity between 0.3 and 1.3 logMAR (i.e., between 20/40 and 20/400) in the amblyopic eye * Visual acuity of 0.3 logMAR (i.e., 20/40) or better in the sound eye * Interocular acuity difference ≥0.3 logMAR * Appropriate refractive error correction for at least 12 weeks

Exclusion criteria

* Presence of an ocular cause of reduced visual acuity * Myopia with a spherical equivalent of -6.0D or more, due to the likely presence of pathological myopia * Prior intraocular surgery * Known skin reaction to patch or bandage adhesive

Design outcomes

Primary

MeasureTime frame
The best corrected logMAR visual acuity score of the amblyopic eye.17 weeks

Secondary

MeasureTime frame
Visual acuity of at least 0.2 logMAR (20/30) and/or improvement of at least 0.2 logMAR from baseline in the amblyopic eye.17 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026